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Forced expression of HOXA1 is sufficient to stimulate oncogenic
transformation of immortalized human mammary epithelial cells
and subsequent tumor formation. We report here that the expres-
sion and transcriptional activity of HOXA1 are increased in mam-
mary carcinomacells at full confluence.This confluence-dependent
expression of HOXA1 was abrogated by incubation of cells with
EGTA to produce loss of intercellular contact and rescued by extra-
cellular addition of Ca2. Increased HOXA1 expression at full con-
fluencewas prevented by anE-cadherin function-blocking antibody
and attachment of non-confluent cells to a substrate by homophilic
ligation of E-cadherin increased HOXA1 expression. E-cadherin-
directed signaling increased HOXA1 expression through Rac1.
Increased HOXA1 expression consequent to E-cadherin-activated
signalingdecreased apoptotic cell death andwas required forE-cad-
herin-dependent anchorage-independent proliferation of human
mammary carcinoma cells. HOXA1 is therefore a downstream
effector of E-cadherin-directed signaling required for anchorage-
independent proliferation of mammary carcinoma cells.
The growth and differentiation of different cell populations during
development are achieved by the coordinated action of complex genetic
programs. Alteration in such regulatory pathways results in oncogenic
transformation and development of neoplastic lesions. Homeotic selec-
tor or homeobox (HOX)2 genes are regulatory genes, which had been
originally identified in Drosophila and encode transcription factors
capable of controlling parallel developmental pathways along the
antero-posterior axis of the embryo (1, 2). They exert genetic control by
activating or repressing the localized expression of downstream effector
genes. The effector genes ofHOXgenes include signalingmolecules and
transcription factors such as sonic hedgehog (3), fibroblast growth fac-
tors (4), bone morphogenetic proteins (5) and polycomb proteins (6)
indicative that HOX genes govern cascades of regulatory pathways.
HOX genes possess a homeobox, which is a 183-bp DNA sequence that
encodes a 61-amino acid sequence termed as the homeodomain usually
situated at the terminal or subterminal position of the corresponding
homeoprotein (7). All HOX genes bind DNA via this homeodomain,
which is a helix-turn-helix DNA binding domain, and many of them
have indistinguishable in vitroDNA recognition properties. In humans,
there are 39HOX genes present in four paralogous gene clusters named
as the HOX-A, HOX-B, HOX-C, and HOX-D, which had been sug-
gested to have resulted by duplication during the course of evolution.
The HOX genes are arranged in a linear order and are shown to be
responsible for patterning the body by control of cell identity, cell
growth, cell differentiation (8), and cell-cell and cell-extracellularmatrix
interactions (9). Recently altered expression of HOX genes have also
been linked to a variety of human cancers, including those of kidney
(includingWilms’ tumor), colon, prostate, skin, and small-cell lung car-
cinoma (10–13).
In the mammary glandHOX genes are expressed in a distinct pattern
during development. For example HOXC6 is expressed during puberty
and at maturity but is not expressed during pregnancy due to its regu-
lation by steroid hormones (14). It has also been demonstrated that the
expression level of certainHOX genes such as HOXA5 andHOXC6 are
repressed in mammary adenocarcinoma (13). HOXA5 has been dem-
onstrated to stimulate mammary carcinoma cell apoptosis by both p53-
dependent and -independentmechanisms (13, 16). In contrast, HOXA1
is not expressed in the differentiated mammary gland but is up-regu-
lated in neoplastic lesions of the human mammary gland (17, 18).
Recently, we have demonstrated that autocrine human growth hor-
mone, a major regulator of human mammary gland development and a
potential human mammary epithelial oncogene (19), up-regulated
HOXA1 in the human mammary epithelial cell (20, 21). HOXA1 stim-
ulates the transcriptional activation of a number of pro-oncogenic mol-
ecules, including cyclinD1 and Bcl-2, thereby permitting increased pro-
liferation and survival of human mammary carcinoma cells (21).
HOXA1 also governs the transcriptional program stimulated by auto-
crine human growth hormone required for autocrine human growth
hormone-stimulated oncogenic transformation of human mammary
epithelial cells, including transcriptional up-regulation of c-Myc, cyclin
D1, and Bcl-2 (19). Forced expression of HOXA1 is sufficient to onco-
genically transform immortalized human mammary epithelial cells,
with consequent soft agar colony formation and aggressive in vivo
tumor formation (21).
Survival of normal epithelial cells depends on signals generated by the
interaction of cells with the basement membrane, and in the absence of
anchorage the cells exhibit the molecular characteristics of apoptosis
and are deleted (22, 23). This form of apoptosis is called anoikis, and it is
believed to preclude epithelial cells from survival, reattachment, and
proliferation outside the appropriate tissue context (24, 25). In contrast,
many carcinoma cells are anoikis-resistant and survive in the absence of
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contact with the basement membrane, inside three-dimensional tumor
nests and in the absence of matrix attachment during metastasis (25).
Some of the mechanisms that confer anoikis resistance on epithelial
cells during tumor progression have been described (25, 26). Previous
work has implicated E-cadherin-mediated cell-cell adhesion in protect-
ing specific epithelium-derived cells from anoikis (27, 28). In addition to
mediation of intercellular adhesion, E-cadherin also stimulates intracel-
lular signaling (29) and has been demonstrated to potentiate cell sur-
vival. It has been demonstrated that E-cadherin suppresses apoptosis of
immortalized granulosa cells (30) and that experimental truncation of
E-cadherin results in potentiation of apoptotic cell death in prostate
epithelial cells (31). N-cadherin can also mediate cell survival in several
cell types (32–34). In addition, E-cadherin has been demonstrated to
stimulate anchorage-independent growth and survival of squamous
carcinoma cells (27).
During the course of our studies on the regulation of HOXA1 in
human mammary carcinoma cells (21), we noted that the expression
and consequent transcriptional activity of HOXA1 was confluence-de-
pendent, suggestive of possible E-cadherin-dependent regulation of
HOXA1. Herein, we demonstrate that E-cadherin-directed signaling
through Rac1 up-regulates HOXA1 in human mammary carcinoma
cells. Increased HOXA1 expression stimulated by E-cadherin-activated
signaling decreased apoptotic cell death and allowed anchorage-inde-
pendent proliferation in human mammary carcinoma cells. Thus,
E-cadherin-mediated intercellular adhesion utilizes HOXA1 to sup-
press apoptosis and promote anchorage-independent growth.
EXPERIMENTAL PROCEDURES
Cell Culture—The MCF-7 and MCF-10A cell lines were obtained
from the ATCC. MCF-7 cells were cultured in RPMI 1640 medium
supplemented with 10% heat-inactivated fetal bovine serum, 100 IU/ml
penicillin, 100 g/ml streptomycin, and 2 mM L-glutamine. MCF-10A
cells were cultured in Dulbecco’s modified Eagle’s medium/F-12
medium (Invitrogen) supplemented with 5% horse serum (Invitrogen)
plus 2 mM glutamine, 100 g/ml streptomycin, 100 IU/ml penicillin,
0.25 g/ml ampicillin B, 100 ng/ml cholera toxin, 20 ng/ml epidermal
growth factor (Upstate Biotechnology, Lake Placid, NY), 0.5 g/ml
hydrocortisone (Calbiochem), and 10 g/ml insulin. The MCF-7 cell
line was stably transfected with a HOXA1 expression plasmid (pSG5-
HOXA1) and pcDNA3 empty vector in a ratio of 5:1 by use of Effectene
transfection reagent obtained fromQiagen as described previously (21).
pSG5-HOXA1 is the generous gift ofDr. VincenzoZappavigna (Milano,
Italy). Positive transfectants were selected in 800 g/ml G418 (Calbio-
chem). Individual colonies were selected to determine the HOXA1
expression level. The cell line MCF7-HOXA1 was established by pool-
ing five individual colonies exhibiting forced expression of HOXA1.
Likewise, MCF-7 cells, stably transfected with vector, were also estab-
lished (MCF7-VECTOR) as control.
Reverse Transcriptase-PCR—Extraction of total RNA and RT-PCR
were performed as described previously (20). To compare the PCR
products semi-quantitatively, 15–40 cycles of PCR (annealing temper-
ature, 55 °C) were performed to determine the linearity of the PCR
amplification, and the amplified -actin cDNA served as an internal
control for cDNA quantity and quality. All RNA samples were treated
with DNase I to avoid genomic DNA contamination.
The sequences of the oligonucleotide primers used for RT-PCR are as
follows: HOXA1 (sense), 5-GGGAAAGTTGGAGAGTACGGC-3;
HOXA1 (antisense), 5-CCTCAGTGGGAGGTAGTCAG-3; -actin
(sense), 5-ATGATATCGCCGCGCTCG-3; and -actin (antisense),
5-CGCTCGGTGAGGATCTTCA-3.
Luciferase Reporter Assay for EphA2-r42B and Bcl-2 Promoter
Constructs—Cells were cultured in six-well plates. Transient transfec-
tion was performed by use of Effectene as described (20). Briefly, 0.2 g
of the respective luciferase constructs (and other constructs as appro-
priate) were transfected per well in serum-free RPMI medium for 12 h
before the medium was changed to fresh serum-free RPMI. 0.2 g of
-galactosidase reporter vector was co-transfected as the control for
transfection efficiency. After a further 24 h, cells were washed with PBS,
and luciferase assays were performed as described previously (21).
-Galactosidase activity was measured in the assay buffer (100 mM
sodium phosphate, pH 7.3, 1 mM MgCl2, 50 mM -mercaptoethanol,
0.665 mg/ml o-nitrophenyl--D-galactopyranoside). Results were nor-
malized to the level of -galactosidase activity and protein concentra-
tion in the samples. EphA2-r42B-LUC was a generous gift of Dr. Jin
Chen (Nashville, TN). The Bcl-2 P1 promoter reporter plasmid was a
kind gift of Dr. John Kurland (Houston, TX).
Real-time PCR—Total RNA was isolated as described above, and the
first strand cDNA synthesis with oligo(dT) primers was performed
using a Reverse Transcription Kit (Applied Biosystems, Newark, NJ)
according to the manufacturer’s instructions. Real-time PCR for
HOXA1 (Inventoried Assay ID Hs00171793-m1, Applied Biosystems)
and glyceraldehyde-3-phosphate dehydrogenase (Inventoried Assay ID
Hs99999905-m1, Applied Biosystems) were performed in triplicate on
1.00 g of cDNA using TaqMan PCRMaster Mix in a reaction volume
of 25 l. PCR amplification and detection was performed using an ABI
Prism 7900 HT (Applied Biosystems). Exponential amplification of all
PCR reactions ranged from 1.95 to 2.00 across seven serial log dilutions
of template. Amplification of a single product for each primer set was
confirmed by dissociation curve analysis, and all products were visual-
ized after electrophoresis on 2% agarose gel. The comparative Ct
method for relative quantification (2Ct) was used to quantitative
gene expression according to the recommendations of Applied Biosys-
tems (7900 HT Real-Time fast and SDS enterprise and data base user
guide). Expression of target genes was normalized to the level of glycer-
aldehyde-3-phosphate dehydrogenase, and the -fold difference was
calculated.
Western Blot Analysis—Cells were treated and harvested as
described. Whole cell lysates were prepared according to the protocol
described (20, 21) and normalized for protein content. Proteins were
resolved by SDS-polyacrylamide (12%) gel electrophoresis, transferred
to a nitrocellulose membrane, and blotted with the antibodies as indi-
cated. The anti--actin, anti-HOXA1, anti-E-cadherin, anti--catenin,
anti--catenin, and anti--catenin antibodies were obtained fromSanta
Cruz Biotechnology (Santa Cruz, CA); immunolabeling was visualized
by using an ECL detection kit fromAmershamBiosciences according to
the manufacturer’s instruction.
Confocal Laser Scanning Microscopy—MCF-7 and MCF10-A cells
were grown in cavity slides to the appropriate confluence (60 or 100%),
fixed in 4% paraformaldehyde/PBS, pH 7.4, washed, and blocked with
BBX (PBS 0.1% Triton, 0.1% bovine serum albumin, 250mMNaCl). The
cells were incubated with anti-HOXA1 and anti-E-cadherin antibodies
overnight at 4 °C. They were again washed and blocked with BBX and
incubatedwith the anti-Goat-TRITCand antimouse-Alexa488 second-
ary antibodies in BBX and mounted. Cells were cultured to the appro-
priate confluence (60 or 100%) and treated with the E-cadherin func-
tion-blocking antibody DECMA-1 or control IgG and processed as
above. Labeled cells were visualized with a Carl Zeiss 510Meta confocal
laser system. Images were converted to the tagged-information-file for-
mat and processed with Adobe Photoshop.
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5-Bromo-2-deoxyuridine Incorporation Assay—Mitogenesis was
directly assayed bymeasuring the incorporation of BrdUrd as described
(20, 21). For incorporation of BrdUrd, subconfluent cells were pulse-
labeled with 20 mM BrdUrd for 30 min, washed twice with PBS, and
fixed in cold 70% ethanol for 30 min. BrdUrd detection was performed
by use of the BrdUrd staining kit from Zymed Laboratories Inc. (San
Francisco, CA) according to the manufacturer’s instructions. A total
population of over three times 300 cells was analyzed in several arbi-
trarily chosen microscopic fields to determine the BrdUrd labeling
index (percentage of cells synthesizing DNA).
Measurement of Apoptosis—Apoptotic cell death was measured by
fluorescent microscopic analysis of cell DNA-staining patterns with
Hoechst 33258 from Sigma Co. (20, 21). Cells were trypsinized with
0.5% trypsin and washed twice with serum-free medium. The cells were
then seeded to glass coverslips in six-well plates and incubated in
serum-free medium with or without E-cadherin expression plasmid,
HOXA1 expression plasmid, DECMA-1, and HOXA1 RNA interfer-
ence (19) as indicated. After a culture period of 24 h, the cells were fixed
in 4% paraformaldehyde in PBS (pH 7.4) and stained with the karyo-
philic dye Hoechst 33258 (20 g/ml) for 10 min at room temperature.
Following washing with PBS, nuclear morphology was examined under
a UV-visible fluorescence microscope (Zeiss Axioplan). Apoptotic cells
were distinguished from viable cells by their nuclear morphology char-
acterized by nuclear condensation and fragmentation as well as the
higher intensity of the blue fluorescence of the nuclei. For statistical
analysis, three times 300 cells were counted in eight random micro-
scopic fields at400 magnification.
Determination of Anchorage-independent Growth of Cells—Cells
were trypsinized and dispensed as either single cells (non-aggregated) or
in aggregated clumps by differential cycles of mechanical aspiration.
Cells (5  104) in suspension culture were grown in 30-mm plastic
bacteriological dishes (Sterilin, Teddington, UK).On the days indicated,
cells were harvested and counted as for monolayers (21).
Calcium Switch—For calcium switch experiments, MCF-7 cells were
seeded into dishes, cultured for 24 h, and then the cells were serum-
starved. After 24-h incubation, E-cadherin-mediated cell-cell contacts
were disrupted by treatment with 4 mM EGTA at 37 °C for 30 min.
Thereafter, intercellular contacts were allowed to reform in the pres-
ence of normal Ca2 containing medium (CaCl2 1.8 mM) at 37 °C for
various time points with or without E-cadherin function-blocking anti-
bodies (DECMA clone-1 at 1:100 dilution, Sigma-Aldrich).
E-cadherin Cell Adhesion Assays (hE/Fc Experiments)—The recom-
binant protein (hE/Fc) consisting of the complete ectodomain of human
E-cadherin fused to the Fc region of IgGwas produced as described (35).
Substrata adsorbed with hE/Fc supported E-cadherin-specific adhesion
and contact formation (36). Using thismodel, E-cadherin engagement is
induced without cell-cell contact (36). For hE/Fc experiments, bacterial
10-cm dishes (precoated with nitrocellulose) were coated with hE/Fc
(50g/ml) for 2 h at room temperature. Blocking of nonspecific binding
sites was performed with 1% bovine serum albumin in Hanks’ balanced
salt solution (HBSS) supplemented with 5 mMCaCl2 for 1 h and 30 min
at room temperature. Dishes were washed five times before addition of
cells. MCF-7 cells were washed once with 10mM EDTA in HBSS/CaCl2
for 1 min and directly trypsinized in 0.01% crystalline trypsin in HBSS/
CaCl2 for 15 min at 37 °C. MCF-7 cells were then washed with HBSS/
CaCl2 and resuspended in HBSS/CaCl2 supplemented with 0.05% fetal
calf serum, seeded onto the 10-cm dishes and incubated at 37 °C. Thirty
minutes after seeding, non-adhered cells were carefully removed by
exchange of media. Five hours after seeding the cells onto the dishes,
RNA and protein extraction were performed.
Statistics—All experiments were repeated at least three to five times.
All numerical data are expressed as mean  S.D. Data were analyzed
using the two-tailed t test or analysis of variance.
RESULTS
HOXA1 mRNA, Protein, and Transcriptional Activity Are Increased
in Mammary Carcinoma Cells at Full Confluence—The level of
HOXA1mRNA inmammary carcinoma cellsMCF-7 at varying degrees
of confluence and at full confluence was first examined by semi-quan-
titative RT-PCR. Fig. 1A demonstrated an amplified fragment of the
FIGURE 1.HOXA1mRNA,protein, and transcrip-
tional activity are increased inmammary carci-
noma cells (MCF-7) at full confluence. MCF-7
cells were cultured at different cellular densities
(20–100% confluence). Experiments were per-
formed as described under “Experimental Proce-
dures.” The level of HOXA1mRNAwas determined
by RT-PCR (A), HOXA1 protein by Western blot
analysis (B), and HOXA1 transcriptional activity by
reporter assay (C) as indicated.-Actinwasused as
loading control. D, MCF-7 cells andmammary epi-
thelial cells (MCF-10A)were cultured at subconflu-
ence (60% confluence) and full confluence (100%
confluence) and the level of HOXA1 mRNA quan-
tified by real-time PCR. *, p 0.01.
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predicted size (359 bp) appropriate for HOXA1 mRNA in MCF-7 cells
(21). HOXA1 mRNA was increased in MCF-7 cells at full confluence
(100% confluence) in comparison to subconfluent conditions (20%,
40%, 60%, and 80% confluences). The level of -actin mRNA did not
differ in MCF-7 cells at different degrees of confluency and was used as
a control for RNA quality (Fig. 1A). To determine if the increased
HOXA1 mRNA observed in MCF-7 cells at full confluence resulted in
increased HOXA1 protein, we examined the level of HOXA1 protein in
MCF-7 cells at the corresponding varying degrees of confluence by
Western blot analysis. Both the 33-kDa and the 35-kDa forms of
HOXA1 were detectable as described previously (21) (Fig. 1B) with
increasedHOXA1protein observed at 100% confluence.Wenext deter-
mined if HOXA1-mediated transcription was consequently increased
inMCF-7 cells at full confluence, by luciferase reporter activity from the
EphA2-r42B enhancer, which contains four HOX-PBX binding sites
(37). MCF-7 cells at full confluence (100% confluence) exhibited
increased luciferase activity from the EphA2-r42B enhancer compared
with MCF-7 cells at subconfluence (20%, 40%, 60%, and 80% conflu-
ences) (Fig. 1C), indicative of increasedHOXA1 transcriptional activity.
To verify the effect of confluence on HOXA1 mRNA expression in
mammary epithelial derived cell lines we utilized quantitative real-time
PCR analysis to determine the expression of HOXA1 at subconfluence
(60%) and confluence (100%) in both MCF-7 cells and a mammary
epithelial (MCF-10A) cell line. In this instance, the expression of
HOXA1 was normalized to the expression of glyceraldehyde-3-phos-
phate dehydrogenase. The relative expression of HOXA1 mRNA was
increased 19- and 7-fold in MCF-7 and MCF-10A cells, respectively, at
confluence compared with subconfluence (Fig. 1D). Thus, confluent
MCF-7 cells exhibited elevated HOXA1-mediated transcriptional
activity compared with subconfluent cultures.
The Increase in HOXA1 Expression inMammary Carcinoma Cells at
Full Confluence Is Cell-Cell Adhesion-dependent—The elevation in
HOXA1 expression in confluent cultures ofMCF-7 cells prompted us to
examine the role of E-cadherin-mediated cell-cell attachment in the
increase in HOXA1 expression that occurs at confluence. We first used
EGTA addition to media to chelate Ca2, thereby disrupting E-cad-
herin-mediated cell-cell contact (38). As shown in Fig. 2A, use of EGTA
completely abrogated the increased expression of HOXA1 mRNA
observed at full confluence in MCF-7 cells. Similarly, analysis of
HOXA1 transcriptional activity by use of the EphA2-r42B enhancer
demonstrated abrogation of increased HOXA1-mediated transcrip-
tional activity in MCF-7 cells at full confluence by EGTA (Fig. 2B).
Luciferase activity generated by a constitutively active luciferase vector
(pSV2-LUC) was not altered in the presence of EGTA (Fig. 2C) indica-
tive that EGTA did not interfere with transcription or translation of the
luciferase reporter.
FIGURE 2. The increase in HOXA1 expression in mammary carcinoma cells at full
confluence is cell-cell adhesion dependent. MCF-7 cells were cultured at subconflu-
ence (60% confluence) and full confluence (100% confluence) in the presence and
absence of EGTA to disrupt cell to cell adhesion. The level of HOXA1 mRNA was deter-
mined by RT-PCR (A) and the level of HOXA1 transcriptional activity was determined by
reporter assay (B). Luciferase activity generated by a constitutively active luciferase vec-
tor (pSV2-LUC) was not altered in the presence of EGTA (C). *, p 0.01.
FIGURE 3. Intercellular adhesion stimulated
increase in HOXA1 is E-cadherin-dependent.
Confluent MCF-7 cells were incubated with 4 mM
EGTA. After 30min, themediumwas replacedwith
RPMI containing Ca2 for the indicated time peri-
ods in the presence of a control IgG or the E-cad-
herin function blocking antibodyDECMA-1. At the
indicated times, cells were lysed and the level of
HOXA1 mRNA was determined by RT-PCR (A and
C) and HOXA1 protein by Western blot analysis
(B and D). -Actin was used as loading control.
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Using the calcium switchmodel inMCF-7 cells (35, 38), we examined
the dynamics of HOXA1mRNA expression by time-lapse analysis (Fig.
3A). E-cadherin-mediated cell-cell adhesionwas abrogated by chelation
of Ca2 and then re-initiated by re-introducing Ca2 (38). This
approach produces a time-dependent accumulation of E-cadherin and
formation of adherens junctions in MCF-7 cells (39). Restoration of
E-cadherin-mediated adhesion by Ca2 significantly increased the
expression of HOXA1mRNA and protein inMCF-7 cells (Fig. 3, A and
B). The increase in HOXA1 mRNA and protein expression was time-
dependent. Increased HOXA1 expression was detected at 15 min
(HOXA1 mRNA) and 30 min (HOXA1 protein) and peaked at 60 min
(HOXA1mRNA) and 90 min (HOXA1 protein) (Fig. 3,A and B). Thus,
the increase in HOXA1 expression in mammary carcinoma cells at full
confluence is mediated by cell-cell adhesion.
MCF-7 cells adhere to each other through not only E-cadherin but
also other adhesionmolecules, and it is therefore possible that cell adhe-
sionmolecules besides E-cadherinmay increaseHOXA1 upon intercel-
lular adhesion. The calcium switch method was therefore performed in
the presence of DECMA-1. MCF-7 cells were incubated with EGTA,
and Ca2 was subsequently restored to the medium in the presence of
DECMA-1, a function-blocking antibody directed against E-cadherin
(40). The increase inHOXA1mRNAand protein expression induced by
calcium restoration was blocked by DECMA-1 (Fig. 3, C and D), indic-
ative that E-cadherin is pivotal for increased HOXA1 expression at full
confluence. Thus, the increase in HOXA1 expression in mammary car-
cinoma cells upon intercellular adhesion is E-cadherin-dependent.
The Increase in HOXA1 Expression inMammary Carcinoma Cells at
Full Confluence Is E-cadherin-dependent—To definitively determine
that increased HOXA1 expression observed in mammary carcinoma
cells at full confluence was due to E-cadherin, we tested the effect of
DECMA-1 on the expression of HOXA1 at subconfluence and conflu-
ence. As is observed in Fig. 4 (A andB), use of DECMA-1 inMCF-7 cells
completely abrogated the increased expression of HOXA1 mRNA and
protein at full confluence. In addition, use of DECMA-1 also diminished
the increased expression of HOXA1 mRNA at full confluence in MCF-
10A cells as demonstrated by real-time PCR analysis (Fig. 4D). Further-
more, use of DECMA-1 in MCF-7 cells abrogated the increased
HOXA1-mediated transcriptional activity at full confluence (Fig. 4C).
FIGURE 4. The increase in HOXA1 expression in
mammary epithelial (MCF-10A) and mammary
carcinoma cells (MCF-7) at full confluence is
E-cadherin-dependent. MCF-7 cells were cul-
tured at subconfluence (60% confluence) and full
confluence (100%confluence) in thepresenceand
absence of DECMA-1, a function-blocking anti-
body against E-cadherin. The level of HOXA1
mRNAwas determined by RT-PCR (A), HOXA1 pro-
tein by Western blot analysis (B), and HOXA1 tran-
scriptional activity by reporter assay (C) as indi-
cated. D, MCF-10A cells were cultured at
subconfluence (60% confluence) and full conflu-
ence (100% confluence) in the presence and
absence of DECMA-1, and the level of HOXA1
mRNAwas quantified by real-time PCR. *, p 0.01.
FIGURE 5. Confocal laser scanning microscopic analysis of the effect of confluence
onHOXA1 expression inmammary epithelial (MCF-10A) andmammary carcinoma
cells (MCF-7). MCF-7 (A–F) and MCF-10A (G–L) cells were cultured at subconfluence
(60%confluence) (D, E, J, and K) and full confluence (100%confluence) (A–C, F,G–I, and L)
in the presence (E, F, K, and L) and absence (A–D andG–J) of DECMA-1. E-cadherin (green)
and HOXA1 (red) were localized as described under “Experimental Procedures.” Arrows
indicate cells exhibiting prominent membrane localization of E-cadherin at the site of
intercellular contact with increased HOXA1 expression.
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Luciferase activity generated by a constitutively active luciferase vector
(pSV2-LUC) was not altered in the presence of DECMA-1 (data not
shown) indicative that DECMA-1 did not interfere with transcription
nor translation of the luciferase reporter.
We also utilized confocal laser scanning microscopy to demonstrate
the effect of confluence and E-cadherin on HOXA1 expression in both
MCF-7 andMCF-10A cells. At full confluence in both cell lines, E-cad-
herin was prominently localized to the membrane at sites of intercellu-
lar contact (Fig. 5, A–C and G–I). In these cells with prominent mem-
brane localization of E-cadherin, we observed increased expression of
HOXA1 relative to subconfluent cells without prominent localization of
E-cadherin to the membrane. Some cells at subconfluence with partial
intercellular contact also exhibited partial localization of E-cadherin to
the membrane and increased HOXA1 expression. Use of DECMA-1
dramatically disrupted E-cadherin localization to the membrane and
decreased the expression of HOXA1 to levels observed in subconfluent
as well as confluent cells in bothMCF-7 andMCF-10A cells (Fig. 5, E, F,
K, and L).
We also examined for a potential physiological association between
the expression of E-cadherin and HOXA1 by use of the Oncomine data
base (www.oncomine.org). We observed a positive correlation (r 	
0.56) between the expression of E-cadherin and HOXA1 mRNAs in
samples of normal mammary gland. Expression of HOXA1 in the
human mammary epithelial cell is therefore E-cadherin-dependent.
The Increase in HOXA1 Expression inMammary Carcinoma Cells at
Full Confluence Is Regulated by E-cadherin-activated Signaling—The
results above do not distinguish whether the increase in HOXA1 at full
confluence is a direct downstream consequence of E-cadherin ligation
or simply a result of juxtacrine signals that required E-cadherin adhe-
sion to bring cell surfaces together. We therefore next delineated
whether increasedHOXA1 expression resulted fromdirect E-cadherin-
activated signals or E-cadherin-dependent juxtacrine signals. To
achieve this, we utilized a recombinant protein (hE/Fc) consisting of the
complete ectodomain of human E-cadherin fused to the Fc region of
IgG. Substrata adsorbed with hE/Fc support E-cadherin-specific con-
tact formation and adhesion of cells (29). Thus, using thismodel, E-cad-
herin homophilic ligation is achieved without cell-cell contact. HOXA1
mRNAwas increased inMCF-7 cells adhered to hE/Fc-coated substrata
in comparison toMCF-7 cells adhered to poly-L-lysine (PLL), whichwas
used as a control to hE/Fc. The level of -actin mRNA did not differ
under the different conditions and was also used as a control for RNA
quality (Fig. 6A). We further examined the level of HOXA1 protein in
MCF-7 cells adhered to either hE/Fc-coated substrata or PLL. As is
observed in Fig. 5B, both the 33- and the 35-kDa forms of HOXA1were
detected, with increased HOXA1 protein observed in MCF-7 cells
adhered to hE/Fc-coated substrata (Fig. 6B). All these experiments were
performed withMCF-7 cells at subconfluence without cell-cell contact.
Thus, increased HOXA1 expression in mammary carcinoma cells
results from direct E-cadherin-activated signaling and not E-cadherin-
dependent juxtacrine signaling.
Rac1 Is Specifically Required for the E-cadherin-activated Increase in
HOXA1 Expression in Mammary Carcinoma Cells—The -, -, and
-catenins, along with E-cadherin, are key components of the adherens
junction (41). To exclude the possibility that confluence alters the
expression of these molecules, we examined their protein levels in
MCF-7 cells at subconfluence and confluence. The levels of E-cadherin
and-,-, and-catenins did not significantly differ between the cells at
subconfluence (60% confluence) and full confluence (100% confluence).
Equal loading of the cell extracts was verified by reprobing the stripped
membrane for -actin (data not shown).
Phosphatidylinositol 3-kinase and Rac1 have been demonstrated to
be directly activated by E-cadherin (29). To determine if phosphatidyl-
inositol 3-kinase or Rac1 was responsible for the E-cadherin-stimulated
increase in HOXA1 expression, we inhibited the activity of phosphati-
FIGURE 6. The increase in HOXA1 expression in
mammary carcinoma cells at full confluence is
regulated by E-cadherin-activated signaling.
SubconfluentMCF-7 cellswere plated onto poly-L-
lysine-coated (PLL) or hE/Fc-coated substrata. The
level of HOXA1 mRNA was determined by RT-PCR
(A) and HOXA1 protein by Western blot analysis
(B). -Actin was used as loading control.
FIGURE7.Rac1 is required for theconfluence-dependent increase inHOXA1expres-
sion in mammary carcinoma cells. MCF-7 cells were cultured at subconfluence (60%
confluence) and full confluence (100% confluence) and transiently transfected with
DNRac1 (dominant negative N17 Rac1mutant) or treated with the phosphatidylinositol
3-kinase inhibitor wortmannin. The N17 Rac1 (DNRac1) mutant abrogated E-cadherin-
increased HOXA1 mRNA expression (A) and HOXA1-mediated transcriptional activity at
full confluence (B), whereas wortmannin (60 nM) did not (A and B). *, p 0.01.
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dylinositol 3-kinase and Rac1 inMCF-7 cells by use of wortmannin and
a dominant negative N17 Rac1 mutant (42), respectively. Transient
expression of the dominant negative N17 Rac1 (dnRac1) mutant signif-
icantly inhibited both the E-cadherin-increased HOXA1 mRNA
expression and increased HOXA1-mediated transcriptional activity at
full confluence (Fig. 7, A and B), whereas wortmannin did not signifi-
cantly affect the level of HOXA1 expression (Fig. 7,A and B). To further
verify the involvement of Rac1 in the direct E-cadherin-stimulated
increase in HOXA1, we examined HOXA1mRNA and protein levels in
MCF-7 cells adhered to hE/Fc or PLL-coated substrata with and with-
out forced expression dnRac1. As is observed in Fig. 8 (A and B), use of
dnRac1 completely prevented the increased HOXA1 mRNA and pro-
tein expression observed in MCF-7 cells adhered to hE/Fc-coated sub-
strata. Thus, Rac1 activity is required for the E-cadherin stimulated
increase in HOXA1 expression in mammary carcinoma cells.
Increased HOXA1 Expression by E-cadherin-activated Signaling
Enhances Survival of Human Mammary Carcinoma Cells—HOXA1
has previously been demonstrated to offer dramatic protection from
apoptosis inMCF-7 cells as a consequence of transcriptional regulation
of Bcl-2 (21). To determine the role of E-cadherin stimulated HOXA1
expression we first constructed a siRNA molecule (19) to deplete the
level of HOXA1 mRNA. Targeting of HOXA1 by siRNA resulted in
depleted HOXA1 mRNA within the cell and abrogated HOXA1-medi-
ated transcriptional activity (Fig. 9). We have previously controlled for
potential off-target effects of this siRNA molecule (19).
We therefore first examined whether increased HOXA1 expression
consequent to E-cadherin-activated signaling would offer protection
from apoptosis inMCF-7 cells. MCF-7 cells at full confluence exhibited
reduced apoptosis compared with MCF-7 cells at subconfluence when
cultured in serum-free medium (Fig. 10A). Transient forced expression
of E-cadherin reduced apoptotic cell death in MCF-7 cells at full con-
fluence (Fig. 10A), whereas it did not significantly alter apoptosis at
subconfluence. The E-cadherin function blocking antibody DECMA-1
completely prevented the decreased apoptotic cell death observed in
MCF-7 cells at full confluence (Fig. 10B), whereas it did not significantly
alter apoptosis in MCF-7 cells at subconfluence. Transient forced
expression of HOXA1 significantly reduced apoptotic cell death in
MCF-7 cells at both confluence and subconfluence (Fig. 10C). Depletion
of HOXA1 by use of HOXA1 siRNA (19) completely abrogated
increased cell survival observed at full confluence and further increased
the apoptotic rate of subconfluent cells (Fig. 10D). HOXA1 siRNA also
prevented the increase in cell survival observed upon forced expression
of E-cadherin in confluent cells (Fig. 10E). If the E-cadherin-activated
increase inHOXA1was required for the observed decrease in apoptosis
at full confluence, we reasoned that inhibition of cell survival by block-
ing of E-cadherin function would be rescued by forced expression of
HOXA1. Transient forced expression of HOXA1 completely reversed
the increase in apoptosis after DECMA-1 inhibition of E-cadherin func-
tion in confluent cells (Fig. 10F). Expression of E-cadherin and HOXA1
for these experiments was verified by Western blot analysis (data not
shown). Thus, increasedHOXA1 expression consequent to E-cadherin-
activated signaling resulted in increased survival of human mammary
carcinoma cells.
The ability of HOXA1 to stimulate cell survival has previously been
demonstrated to be mediated by transcriptional activation of the Bcl-2
gene via the P1 promoter (21). Similarly, E-cadherin has also been dem-
onstrated to regulate the expression of Bcl-2 tomediate cellular survival
(28). We therefore examined the effect of cell confluence on mammary
carcinoma cell transcription of the Bcl-2 gene to provide a mechanism
for the above observed effects. Mammary carcinoma cells at full conflu-
ence exhibited significantly higher activation of the Bcl-2 promoter
compared with cells at subconfluence (Fig. 11). Disruption of E-cad-
herin with DECMA-1, or depletion of HOXA1 with siRNA, both
reduced the confluence dependent increase in Bcl-2 gene transcription.
Furthermore, forced expression of E-cadherin increased Bcl-2 pro-
moter activity as did forced expression of HOXA1. The E-cadherin-
stimulated increase in Bcl-2 promoter activity at full confluence was
abrogated by siRNA-mediated depletion of HOXA1 (Fig. 11). The
E-cadherin-stimulated increase in Bcl-2 gene transcription is therefore
dependent on HOXA1 in accord with HOXA1-mediated cell survival
stimulated by E-cadherin at confluence.
We also examined the effect of confluence on MCF-7 cell cycle pro-
gression by examination of the nuclear incorporation of 5-bromo-2-
deoxyuridine (BrdUrd). MCF-7 cells at full confluence did not exhibit a
significantly higher percentage of nuclear BrdUrd incorporation com-
pared with MCF-7 cells at subconfluence (Fig. 12). Thus, E-cadherin
FIGURE 8. Rac1 is required for the E-cadherin-
activated increase in HOXA1 expression in
mammary carcinoma cells. Subconfluent MCF-7
cells transiently transfected with vector or
N17Rac1 were plated onto poly-L-lysine-coated
(PLL) or hE/Fc-coated substrata. N17Rac1 pre-
vented the increased HOXA1 mRNA (A) and pro-
tein (B) observed in MCF-7 cells adhered to hE/Fc-
coated substrata. -Actin was used as loading
control.
FIGURE 9. siRNA mediated depletion of HOXA1. siRNA to HOXA1 was generated as
described under “Experimental Procedures.” MCF-7 cells were transiently transfected
with HOXA1 siRNA.A, RT-PCRwas utilized to demonstrate depletion of HOXA1mRNAby
siRNA. B, siRNA abrogation of HOXA1-mediated transcriptional activity.
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ligation does not result in a proliferative signal inMCF-7 cells in mono-
layer culture. Depletion of HOXA1 by use of siRNA to HOXA1 dimin-
ished BrdUrd incorporation in both subconfluent and confluent culture
in accord with our previous demonstration that HOXA1 stimulates,
albeit minimally, MCF-7 cell cycle progression (21).
Increased HOXA1 Expression by E-cadherin-activated Signaling
Increases Anchorage-independent Proliferation in Human Mammary
Carcinoma Cells—E-cadherin has previously been demonstrated to
mediate aggregation-dependent survival of epithelium-derived cells
(27, 28, 31). To determine the effect of increased HOXA1 expression by
E-cadherin-activated signaling on anchorage-independent proliferation
in MCF-7 cells, we examined the growth of non-aggregated and aggre-
gated MCF-7 cells in suspension culture. Aggregated MCF-7 cells
increased in number significantly greater than non-aggregated MCF-7
FIGURE 10. IncreasedHOXA1expressionby E-cadherin-activated signalingdecreases apoptotic cell death in humanmammary carcinoma cells.MCF-7 cells were cultured at
subconfluence (60% confluence) and full confluence (100% confluence) and transiently transfected with an E-cadherin expression plasmid (A and E), HOXA1 expression plasmid (C
and F), HOXA1 RNAi (E and F), or treated with DECMA-1 (E-cadherin function-blocking antibody) (B and F) and apoptotic cell death determined as detailed under “Experimental
Procedures.” Expression of E-cadherin at confluence increased cell survival (A and E); DECMA-1 prevented confluence-dependent cell survival (B and F); HOXA1 RNAi prevented the
increased cell survival at full confluence (D), evenwith forcedexpressionof E-cadherin (E). Blockingof E-cadherin functionprevented confluencedependent cell survival (B and F); and
expression of HOXA1 rescued loss of E-cadherin function (F). *, p 0.01.
FIGURE 11. E-cadherin dependent stimulation
of Bcl-2 promoter activity is HOXA1-
dependent. MCF-7 cells were transiently trans-
fected with the respective plasmids as indicated
with or without DECMA-1. Luciferase assays for
determination of Bcl-2 promoter activitywere per-
formed as described under “Experimental Proce-
dures” and normalized to constitutive -galacto-
sidase activity. *, p 0.01.
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cells in suspension culture and after 5 days had approximately doubled
in number (Fig. 13A). In contrast, non-aggregated MCF-7 cells exhib-
ited a slow decline in number and at 5 days were 50% of the original
plating number. Depletion of HOXA1 levels by HOXA1 siRNA inhib-
ited anchorage-independent growth of aggregated MCF-7 cells (Fig.
13B). Furthermore, DECMA-1 prevented anchorage-independent
growth of aggregated MCF-7 cells but not of aggregated MCF-7 cells
with forced stable expression of HOXA1 (Fig. 13C). Thus, increased
HOXA1 expression consequent to E-cadherin-activated signaling is
required for anchorage-independent proliferation of human mammary
carcinoma cells.
DISCUSSION
We have demonstrated herein that E-cadherin homophilic ligation
stimulates the expression of HOXA1 in a Rac1-dependent manner.
HOXA1 is subsequently utilized by E-cadherin to execute a program of
cell survival and permits E-cadherin to stimulate anchorage-indepen-
dent proliferation of humanmammary carcinoma cells.We have there-
fore identified HOXA1, a powerful human mammary epithelial onco-
gene (21), as an effector molecule of E-cadherin.
In the normalmammary gland E-cadherin is expressed by the luminal
epithelial cells and is localized to sites of intercellular contact (43). A
large number of studies have demonstrated a loss of E-cadherin in the
majority of lobular carcinomas of the mammary gland (44–46). How-
ever, this type of carcinoma represents aminority of carcinomas derived
from the mammary epithelial cell. In contrast to lobular carcinomas,
most ductal carcinomas retain E-cadherin expression, although the
actual level of expression may vary (44–47). In this regard, E-cadherin-
activated HOXA1 will be a mechanism to provide a contact-dependent
survival signal independent of integrins (25). In general, E-cadherin
expression is higher in well differentiated and less invasive tumors as
opposed to poorly differentiated or invasive tumors (48). Although
E-cadherin expression does not correlate with lymph node status of
mammary tumors (49), a number of experimental studies indicate a role
of E-cadherin inmetastatic progression. For example, forced expression
of E-cadherin in E-cadherin negative mammary carcinoma cells sup-
presses metastasis in a xenograft model (50) and tamoxifen restores the
function of E-cadherin in human mammary carcinoma cells and sup-
presses their invasive phenotype (51). Expression of HOXA1 has also
been demonstrated to increase in neoplastic lesions of the mammary
gland (17, 18), although comprehensive analysis of the tumor stages or
subtypes was not performed. It is well documented that mammary car-
cinoma cell behavior may be altered by autonomous expression of mol-
ecules involved in cell survival and/or proliferation (52). E-cadherin
autonomous expression of HOXA1 may offer a molecular strategy for
the cell to dispense with E-cadherin, opening the possibility for cells to
down-regulate E-cadherin to undergo epitheliomesenchymal transition
(EMT), invasion and potential metastasis while remaining resistant to
anoikis. Indeed, our unpublished observations3 have demonstrated that
HOXA1 itself does not stimulate EMT in human mammary carcinoma
cells nor any morphological or functional changes consequent to EMT.
Furthermore, although we observed a positive correlation between the
expression level of E-cadherin and HOXA1 in normal/benign mam-
mary tissue in the Oncomine data base, no such correlation was
observed in samples of invasive mammary carcinoma within the same
data base. Thus, E-cadherin utilizes HOXA1 specifically for cell survival
and not for maintenance of the epithelial phenotype and potential
autonomous expression of HOXA1 will release the mammary carcinoma
cell from the requirement of E-cadherin to prevent anoikis. Alternatively,
dysregulation of Rac1 in neoplastic progression may contemporaneously
down-regulate E-cadherin-mediated intercellular adhesion (53) and up-
regulate HOXA1, providing carcinoma cells with the opportunity to
escape anoikis while undergoing EMT.
We have previously demonstrated that forced expression of HOXA1
dramatically enhances anchorage-independent proliferation of mam-
mary carcinoma cells and allows anchorage-independent growth of
non-transformed human mammary epithelial cells (21). The effects of
HOXA1 on increasing cell survival and preventing anoikis required the
transcriptional up-regulation of Bcl-2 via the P1 promoter (21). Thus,
Bcl-2 knockdown or inhibition of Bcl-2 function prevented the cell sur-
vival-promoting actions of HOXA1 in the mammary carcinoma cell. In
3 X. Zhang and P. E. Lobie, unpublished observations.
FIGURE 12. Effect of cell confluence onmammary carcinoma cell cycle progression.
MCF-7 cells transiently transfectedwith vector orHOXA1 siRNAwere cultured at subcon-
fluence (60% confluence) and full confluence (100% confluence) and nuclear incorpora-
tion of BrdUrd determined as described under “Experimental Procedures.”
FIGURE 13. Increased HOXA1 expression by E-cadherin-activated signaling increases anchorage-independent proliferation of humanmammary carcinoma cells. Anchor-
age-independent growth of aggregated and separate MCF-7, MCF7-VECTOR, and MCF7-HOXA1 cells in bacteriological dishes were performed as described under “Experimental
Procedures.” Aggregated cells increased in number in suspension culture (A). Use of HOXA1 RNAi inhibited anchorage-independent growth of aggregated MCF-7 cells (B), and
DECMA-1 prevented anchorage-independent growth of MCF7-VECTOR but not MCF7-HOXA1 cells (C). *, p 0.01.
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addition, forced expression ofHOXA1produced resistance to apoptosis
induced by doxorubicin, another effect mediated by the HOXA1-stim-
ulated increase in Bcl-2 (21). In this regard it is interesting that MCF-7
cells exhibit relative chemoresistancewhen grown as three-dimensional
spheroids as opposed to culture as two-dimensional monolayers (54).
Functional disruption of E-cadherin was reported to increase the che-
mosensitivity of MCF-7 cells in three-dimensional culture indicative
that E-cadherin-mediated intercellular contact produced chemoresis-
tance (54). Decreased chemosensitivity of ovarian carcinoma cells
grown in spheroids as opposed to monolayer culture has been demon-
strated to be associatedwith enhanced expression of Bcl-XL (55). E-cad-
herin-mediated intercellular contact has recently been demonstrated to
increase Bcl-2 in squamous cell carcinoma by EGF-R-dependent acti-
vation of p44/42MAP kinase (28). In this regard it is interesting that we
have demonstrated that HOXA1 itself regulates the expression of com-
ponents of the pathway used for activation of p44/42 MAP kinase,
including Grb2 and MEK1, and results in dramatically elevated p44/42
MAP kinase-dependent transcriptional activity.4 Thus, E-cadherin reg-
ulation of HOXA1 will potentially prime or sensitize the cell to activa-
tors of the p44/42 MAP kinase pathway. E-cadherin may potentially
utilize HOXA1 to increase expression of Bcl-2 analogous to the use of
HOXA1 by autocrine human growth hormone (19) to transcriptionally
activate molecules, including Bcl-2, required for cell survival.
Classic cadherins can regulate cell signaling via a number of general
mechanisms. These include serving as upstream receptors to activate
signaling pathways and mediating juxtacrine signaling (29). Our data
show that not only is E-cadherin necessary for cell-cell contact to stim-
ulate HOXA1, but homophilic ligation itself, induced using recombi-
nant E-cadherin adhesive ligands, is sufficient to induce the expression
of this key transcription factor. Our current data therefore identifies
HOXA1 as a critical transcriptional target for “direct” cadherin-acti-
vated cell signaling. A number of signaling pathways can be activated by
cadherin homophilic ligation, including small GTPases of the Rho fam-
ily, lipid kinases, and receptor tyrosine kinases. Notably, a key pathway
activated by classic cadherins such as E-, C-, andN-cadherin (42, 56, 57)
involves the small GTPase, Rac. This is best understood to regulate the
cortical actin cytoskeleton at cadherin adhesive contacts. However, Rac
is also known to regulate transcriptional events (29), consistent with our
observation that HOXA1 expression depended on Rac, but not phos-
phatidylinositol 3-kinase, signaling. This further defines HOXA1 as a
transcriptional target of the cadherin-activated Rac signaling pathway.
Interestingly, inhibition of Rac1 by a newly developed small molecule
inhibitor has been demonstrated to inhibit anchorage-independent
proliferation of human prostatic carcinoma cells (58), an effect poten-
tially mediated by HOXA1.
The mammary gland is one of very few organs that are subjected to
substantial postnatal development; cycles of growth, differentiation,
apoptosis, regression, and remodeling aremaintained almost during the
lifetime of the organism (59). In this regard, the association between
E-cadherin and HOXA1 is interesting given the pivotal developmental
role of E-cadherin (60, 61) and members of the homeobox family of
genes in general (10, 11). E-cadherin is expressed at all stages of mam-
mary development (43). It is predominantly localized to ductal luminal
cells and end bud body cells. Exposure of end buds to a function block-
ing E-cadherin antibody disrupts the body epithelium (62). In addition,
mammary-specific inactivation of E-cadherin resulted in massive cell
death at parturition to produce a gland that resembled the involuted
gland normally observed after weaning (63). Similarly, deletion of three
paralogous homeobox genes, Hoxa9, Hoxb9, and Hoxd9, produce hyp-
oplasia of the mammary gland during pregnancy and post parturition
(64). Although E-cadherin has been only demonstrated to date to regu-
late HOXA1 (this study), it is likely that E-cadherin will regulate other
members of the HOX family to direct specific developmental programs
in the mammary gland. One potential physiological function of E-cad-
herin-regulated HOXA1 may be to provide the capacity for luminal
filling during virgin ductal development where resistance to anoikis
would be required. Another may be to provide cell-survival functions
important for initiation and maintenance of lactation. In any case, the
ability of E-cadherin to regulate HOXA1 expression for anchorage-in-
dependent growth of mammary carcinoma cells will be a pathological
recapitulation of a normal developmental function.
In conclusion, we have demonstrated that increased HOXA1 expres-
sion and transcriptional activity upon formation of intercellular con-
tacts in mammary carcinoma cells was mediated by E-cadherin activa-
tion of Rac1. E-cadherin utilized HOXA1 to increase cell survival and
facilitate anchorage-independent proliferation. HOXA1 is therefore a
downstream effector molecule of E-cadherin-directed signaling.
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